Forgot your password?
New user?
Document Actions
Survival of the fittest
by
Matt Wilkinson, RSC
—
last modified
06-12-09 04:34 AM
Copyright 2009, RSC
Many small pharma and biotech firms are struggling to raise enough cash to survive. © Corbis
With the increasing importance that big pharma is placing on biological medicines, the rate at which biopharmaceutical and life science companies are running out of money is truly astonishing.
While the pharmaceutical and biopharmaceutical sectors in general are outperforming broader stock market trends, many early stage companies are desperately trying to conserve cash and raise money to keep going.
More: http://www.rsc.org/chemistryworld/News/2009/April/21040901.asp
Researchers discover new materials to capture methane